Blurbs

Analysts Offer Insights on Healthcare Companies: Sol-Gel Technologies (SLGL), Zentalis Pharmaceuticals (ZNTL) and Oncology Institute, Inc. (TOI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies (SLGLResearch Report), Zentalis Pharmaceuticals (ZNTLResearch Report) and Oncology Institute, Inc. (TOIResearch Report) with bullish sentiments.

Sol-Gel Technologies (SLGL)

Raymond James analyst Elliot Wilbur maintained a Buy rating on Sol-Gel Technologies today and set a price target of $13.00. The company’s shares closed last Friday at $4.74, close to its 52-week low of $3.94.

According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of -10.7% and a 35.1% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Perrigo Company, PolyPid, and Petiq.

Sol-Gel Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.

See today’s best-performing stocks on TipRanks >>

Zentalis Pharmaceuticals (ZNTL)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Zentalis Pharmaceuticals, with a price target of $55.00. The company’s shares closed last Friday at $21.01, close to its 52-week low of $17.33.

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 6.5% and a 51.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Zentalis Pharmaceuticals is a Strong Buy with an average price target of $45.50, which is a 126.3% upside from current levels. In a report issued on November 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $58.00 price target.

Oncology Institute, Inc. (TOI)

Guggenheim analyst Sandy Draper maintained a Buy rating on Oncology Institute, Inc. today and set a price target of $6.00. The company’s shares closed last Friday at $2.38.

According to TipRanks.com, Draper is ranked #141 out of 8077 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncology Institute, Inc. with a $8.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SLGL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More